Global robotics funding hit $18.8 billion year-to-date in 2026, already surpassing all of 2025's $15 billion with five months remaining. The surge is heavily driven by Chinese humanoid-robotics companies preparing for public listings. LimX Dynamics, founded in 2022, raised $200 million at a $2.2 billion pre-IPO valuation in July, joining the race to go public. Combined with a $200 million Series B in February, LimX has raised $400 million in six months. The company is developing fully autonomous, general-purpose humanoid robots for commercial deployment in the Middle East, Europe, and Asia.
This marks a tectonic shift in robotics funding geography and strategy. Western robotics startups (Figure AI, Agility Robotics, Apptronik) previously dominated venture attention. Now, Chinese companies command comparable or larger checks, backed by domestic manufacturing supply chains that confer cost advantages. Founder Zhang Wei argues that humanoid-robotics technology has passed the "0 to 1" innovation line and that execution—scaling production and deployment—is now the barrier. LimX aims to ship thousands of robots; competitor Unitree is also pursuing an IPO. Approximately 20 Chinese startups now have >10 billion yuan valuations.
For practitioners evaluating embodied AI and robotics deployment, the concentration of capital in Chinese humanoids and the push toward public listings signal a market inflection: valuations are running ahead of demonstrated commercial deployment at scale. However, the funding velocity suggests customers and industrial partners (Lens Technology, GGG, Stone Venture) believe near-term commercialization risk is acceptable. The robotics category is now capital-intensive ($18.8B in 2026); top 10 deals account for 74% of capital, indicating consolidation around full-stack platforms.